5568-33-2

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-4-nitrobenzaldehyde is used as a key intermediate in the preparation of nitrogen heterocyclic compounds, which serve as ErbB inhibitors. These inhibitors are crucial for the treatment of cancer, as they target the ErbB family of receptor tyrosine kinases, which play a significant role in cell growth and differentiation. By inhibiting these receptors, the growth and proliferation of cancer cells can be effectively controlled.

InChI:InChI=1/C7H4ClNO3/c8-7-3-6(9(11)12)2-1-5(7)4-10/h1-4H

Upstream product

• 42533-63-1 1-(bromomethyl)-2-chloro-4-nitrobenzene 
• 121-86-8 2-chloro-4-nitrotoluene 
• 64-17-5 ethanol 
• 77455-65-3 3-chloro-4-(dichloromethyl)-1-nitrobenzene 
• 77455-54-0 2-chloro-4-nitrobenzal diacetate 
• 75-17-2 formaldoxime 
• 52301-88-9 (2-chloro-4-nitrophenyl)methanol 
• 7073-36-1 2-chloro-4-nitrobenzoyl chloride 
• 179687-05-9 2-chloro-N-methoxy-N-methyl-4-nitrobenzamide 
• 85544-62-3 1-dimethylamino-2-(2'-chloro-4'-nitrophenyl)-ethylene 

Downstream Products

• 54439-75-7 2-chloro-4-methoxybenzaldehyde 
• 99-60-5 2-chloro-4-nitrobenzoic acid 
• 15866-69-0 1-Phenyl-4-(2-chlor-4-nitrophenyl)butadien 
• 4402-95-3 3-(2-chloro-4-nitro-phenyl)-5-methyl-isoxazole-4-carboxylic acid methyl ester 
• 77455-65-3 3-chloro-4-(dichloromethyl)-1-nitrobenzene 
• 112969-07-0 4-(2-chloro-4-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester 
• 31368-22-6 2-Chloro-5-[(E)-2-(2-chloro-4-nitro-phenyl)-vinyl]-benzenesulfonyl fluoride 
• 31368-18-0 2-Chloro-4-[(E)-2-(2-chloro-4-nitro-phenyl)-vinyl]-benzenesulfonyl fluoride 
• 31368-17-9 3-Chloro-4-[(E)-2-(2-chloro-4-nitro-phenyl)-vinyl]-benzenesulfonyl fluoride 
• 31368-20-4 4-Chloro-2-[(E)-2-(2-chloro-4-nitro-phenyl)-vinyl]-benzenesulfonyl fluoride 
• 31368-19-1 5-Chloro-2-[(E)-2-(2-chloro-4-nitro-phenyl)-vinyl]-benzenesulfonyl fluoride 
• 198821-76-0 3-chloro-4-(oxazol-5-yl)phenylamine 
• 198821-75-9 5-(2-chloro-4-nitrophenyl)-1,3-oxazole 
• 179687-02-6 (2-chloro-4-nitrophenyl)(pyridin-2-yl)methanol 

Relevant academic research and scientific papers

NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.

Combined production method for substituted benzaldehyde, substituted benzyl alcohol and substituted benzoic acid

The invention discloses a combined production method for substituted benzaldehyde, substituted benzyl alcohol and substituted benzoic acid. The method comprises the following steps: (1) oxidation: a step of continuously introducing substituted toluene, a catalyst and oxygen-contained gas into an oxidation reactor and carrying out reaction so as to obtain oxidation reaction liquid; (2) hydrolyzation: a step of allowing the oxidation reaction liquid to continuously enter a hydrolysis reactor, and continuously adding water into the hydrolysis reactor and carrying out reaction so as to obtain a hydrolysis reaction mixture; (3) liquid-liquid layering: a step of layering the hydrolysis reaction mixture so as to obtain an oil phase and an aqueous phase; and (4) separation of products: a step of subjecting the oil phase to distillation so as to respectively obtain incompletely-reacted substituted toluene, substituted benzyl alcohol and substituted benzaldehyde, and subjecting the aqueous phase to cooling, crystallizing and filtering so as to obtain filtrate and substituted benzoic acid. The combined production method provided by the invention has the advantages of high raw material conversion rate, few by-products, good selectivity of target products, greenness and environmental protection.

Facile, environmentally friendly synthesis of benzaldehyde and phenylacetaldehyde analogs from readily available toluene derivatives

A facile environmentally friendly synthesis of bezaldehyde and phenylacetaldehyde analogs from readily available toluene derivatives is described. Oxidation of the styrylamines by H2O2 H2O2 affords benzaldehydes in moderate yields, while the hydrolysis of styrylamines afforded phenylacetaldehyde analogs in good yields. Copyright

Synthesis, larvicidal activity, and SAR studies of new benzoylphenylureas containing oxime ether and oxime ester group

A series of new structural benzoylphenylureas (BPUs) containing oxime ether and oxime ester group were designed and synthesized. The larvicidal activities against Oriental armyworm and mosquito of these benzoylphenylureas were evaluated and the result of bioassay displayed specific structure-activity relationship (SAR). Most of the compounds exhibited excellent larvicidal activities against Oriental armyworm and mosquito. Interestingly, some compounds showed different structure-activity relationship towards diamondback moth, beet armyworm, and corn borer although three tested insects all belong to the same insect order.

BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS

A compound according to formula I: or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3a, R3b, R3c and R3d are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

PURINES AS PKC-THETA INHIBITORS

A chemical genus of purines, which are useful as PKCθ inhibitors, is disclosed. The genus is represented by the formula (I); A representative example is: (II)

Orally active CCR5 antagonists as anti-HIV-1 agents 2: Synthesis and biological activities of anilide derivatives containing a pyridine N-oxide moiety

In order to develop orally active CCR5 antagonists, we investigated 1-benzoxepine derivatives containing new polar substituents, such as phosphonate, phosphine oxide or pyridine N-oxide moieties, as replacements for the previoiusly reported quaternary ammonium moiety. Among these compounds, the 2-(α-hydroxybenzyl)pyridine N-oxide 5e exhibited moderate CCR5 antagonistic activity and had an acceptable pharmacokinetic profile in rats. Subsequent chemical modification was performed and compound (S)-5f possessing the (S)-configuration hydroxy group was found to be more active than the (R)-isomer. Replacement of the 1-benzoxepine ring with a 4-methylphenyl group by a 1-benzazepine ring with a 4-[2-(butoxy)ethoxy]phenyl group enhanced the activity in the binding assay. In addition, introduction of a 3-trifluoromethyl group on the phenyl group of the anilide moiety led to greatly increased activity in the HIV-1 envelope-mediated membrane fusion assay. In particular, compound (S)-5s showed the most potent CCR5 antagonistic activity (IC 50=7.2 nM) and inhibitory effect (IC50=5.4 nM) in the fusion assay, together with good pharmacokinetic properties in rats.

Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-methoxy-4-(5-oxazolyl)phenyl moiety

The first reported structure-activity relationships (SARs) about the N-[3-methoxy-4-(5-oxazolyl)phenyl moiety for a series of recently disclosed inosine monophosphate dehydrogenase (IMPDH) inhibitors are described. The syntheses and in vitro inhibitory values for IMPDH II, and T-cell proliferation (for select analogues) are given.

Novel diamide-based inhibitors of IMPDH

A series of novel amide-based small molecule inhibitors of inosine monophosphate dehydrogenase is described. The synthesis and the structure-activity relationships (SARs) derived from in vitro studies are presented.

Inhibitors of IMPDH enzyme

The present invention relates to a novel class of compounds which are IMPDH inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.